ANIX
Price
$3.12
Change
-$0.11 (-3.41%)
Updated
Mar 28, 6:59 PM EST
70 days until earnings call
DARE
Price
$0.49
Change
-$0.06 (-10.91%)
Updated
Mar 28, 6:59 PM EST
41 days until earnings call
Ad is loading...

ANIX vs DARE ᐉ Comparison: Which is Better to Invest?

Header iconANIX vs DARE Comparison
Open Charts ANIX vs DAREBanner chart's image
Anixa Biosciences
Price$3.12
Change-$0.11 (-3.41%)
Volume$89.59K
CapitalizationN/A
Dare Bioscience
Price$0.49
Change-$0.06 (-10.91%)
Volume$361.35K
CapitalizationN/A
View a ticker or compare two or three
ANIX vs DARE Comparison Chart

Loading...

ANIXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
DAREDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ANIX vs. DARE commentary
Mar 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIX is a Hold and DARE is a Hold.

COMPARISON
Comparison
Mar 29, 2024
Stock price -- (ANIX: $3.12 vs. DARE: $0.49)
Brand notoriety: ANIX and DARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANIX: 92% vs. DARE: 131%
Market capitalization -- ANIX: $99.53M vs. DARE: $48.32M
ANIX [@Biotechnology] is valued at $99.53M. DARE’s [@Biotechnology] market capitalization is $48.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $570.99B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIX’s FA Score shows that 0 FA rating(s) are green whileDARE’s FA Score has 0 green FA rating(s).

  • ANIX’s FA Score: 0 green, 5 red.
  • DARE’s FA Score: 0 green, 5 red.
According to our system of comparison, DARE is a better buy in the long-term than ANIX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIX’s TA Score shows that 5 TA indicator(s) are bullish while DARE’s TA Score has 3 bullish TA indicator(s).

  • ANIX’s TA Score: 5 bullish, 3 bearish.
  • DARE’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ANIX is a better buy in the short-term than DARE.

Price Growth

ANIX (@Biotechnology) experienced а -15.45% price change this week, while DARE (@Biotechnology) price change was +3.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.98%. For the same industry, the average monthly price growth was +8.91%, and the average quarterly price growth was +90.55%.

Reported Earning Dates

ANIX is expected to report earnings on Jun 07, 2024.

DARE is expected to report earnings on May 09, 2024.

Industries' Descriptions

@Biotechnology (+4.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ANIX with price predictions.
OPEN
A.I.dvisor published
a Summary for DARE with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ANIX($99.5M) has a higher market cap than DARE($48.3M). DARE YTD gains are higher at: 58.641 vs. ANIX (-19.588). ANIX has higher annual earnings (EBITDA): -12.02M vs. DARE (-41.96M). ANIX has more cash in the bank: 23.8M vs. DARE (13.9M). ANIX has less debt than DARE: ANIX (162K) vs DARE (195K). DARE has higher revenues than ANIX: DARE (1M) vs ANIX (210K).
ANIXDAREANIX / DARE
Capitalization99.5M48.3M206%
EBITDA-12.02M-41.96M29%
Gain YTD-19.58858.641-33%
P/E RatioN/AN/A-
Revenue210K1M21%
Total Cash23.8M13.9M171%
Total Debt162K195K83%
FUNDAMENTALS RATINGS
ANIX vs DARE: Fundamental Ratings
ANIX
DARE
OUTLOOK RATING
1..100
644
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
7549
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DARE's Valuation (70) in the Biotechnology industry is in the same range as ANIX (75) in the Computer Peripherals industry. This means that DARE’s stock grew similarly to ANIX’s over the last 12 months.

DARE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ANIX (100) in the Computer Peripherals industry. This means that DARE’s stock grew similarly to ANIX’s over the last 12 months.

ANIX's SMR Rating (97) in the Computer Peripherals industry is in the same range as DARE (100) in the Biotechnology industry. This means that ANIX’s stock grew similarly to DARE’s over the last 12 months.

DARE's Price Growth Rating (49) in the Biotechnology industry is in the same range as ANIX (75) in the Computer Peripherals industry. This means that DARE’s stock grew similarly to ANIX’s over the last 12 months.

DARE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ANIX (100) in the Computer Peripherals industry. This means that DARE’s stock grew similarly to ANIX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIXDARE
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
81%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 23 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Ad is loading...
ANIXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
DAREDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BCTX2.850.18
+6.74%
BriaCell Therapeutics Corp
EVBG34.820.01
+0.03%
Everbridge
BPMC94.79N/A
N/A
Blueprint Medicines Corp
UBS30.72-0.68
-2.17%
UBS Group AG
FRGE1.93-0.15
-7.21%
Forge Global Holdings

ANIX and

Correlation & Price change

A.I.dvisor tells us that ANIX and CDTX have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ANIX and CDTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANIX
1D Price
Change %
ANIX100%
-3.41%
CDTX - ANIX
27%
Poorly correlated
+9.26%
SER - ANIX
25%
Poorly correlated
-9.49%
CLRB - ANIX
25%
Poorly correlated
+9.49%
AGE - ANIX
25%
Poorly correlated
N/A
CRSP - ANIX
24%
Poorly correlated
-2.85%
More

DARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, DARE has been loosely correlated with CYTK. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DARE jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DARE
1D Price
Change %
DARE100%
-10.71%
CYTK - DARE
42%
Loosely correlated
-1.82%
AXON - DARE
39%
Loosely correlated
-0.98%
AMRN - DARE
34%
Loosely correlated
+0.18%
TRVN - DARE
32%
Poorly correlated
+0.31%
ORMP - DARE
31%
Poorly correlated
+3.55%
More